DOCSLIB.ORG

Effects of Intraoperative Angiotensin-Converting Enzyme Inhibition by Quinaprilat on Gastric Mucosal Blood Flow During Cardiopulmonary Bypass in Humans M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Intraoperative Angiotensin-Converting Enzyme Inhibition by Quinaprilat on Gastric Mucosal Blood Flow During Cardiopulmonary Bypass in Humans M Effects of intraoperative angiotensin-converting enzyme inhibition ... 43 Applied Cardiopulmonary Pathophysiology 14: 43-50, 2010 Effects of intraoperative angiotensin-converting enzyme inhibition by quinaprilat on gastric mucosal blood flow during cardiopulmonary bypass in humans M. Müller1, M. Kwapisz1, S. Klemm1, H. Maxeiner1, H. Akintürk2, K. Valeske2 University Hospital Gießen and Marburg GmbH, Campus Gießen: 1Department of Anaes- thesiology, Intensive Care Medicine and Pain Therapy; 2Department of Cardiovascular Sur- gery Abstract Laser Doppler flow (LDF) assessment and regional carbon dioxide measurements by air tonom- etry were performed to estimate the changes in gastric mucosal blood flow after angiotensin- converting enzyme (ACE) inhibition in patients undergoing cardiopulmonary bypass (CPB). Patients scheduled for elective CABG were prospectively assigned to group A (quinaprilat 0.02 mg/kg, n = 10), group B (quinaprilat 0.04 mg/kg, n = 10), or group C (control, n = 10). Base- line values were measured after induction of anesthesia (T0) and repeated during steady state CPB (T1). Thereafter either quinaprilat, a non-sulphydryl ACE inhibitor, (group A and B) or saline solution (group C) were given as an intravenous bolus. The LDF measurements were per- formed after 5 (T2), 10 (T3), 15 (T4) minutes during CPB as well as 5 minutes after weaning off CPB (T5) and at the end of surgery (T6). The tonometric measurements were repeated at T4, T5 and T6. During hypothermic CPB LDF decreased in all groups. In group B only, LDF returned to base- line after application of quinaprilat. At the end of surgery (T6) LDF returned to baseline in group A and C, too. In group B LDF was significantly higher at T3, T4, T5 and T6 compared to control (p < 0.05). No difference between the groups as well as over the time course could be seen with regard to carbon dioxide tension of the gastric mucosa. The results of the LDF measurements suggests a selective increase in gastric mucosal blood flow after ACE inhibition. Key words: laser doppler flowmetry, tonometry, angiotensin-converting enzyme inhibition, quinaprilat, cardiac surgery, cardiopulmonary bypass, gastric mucosal blood flow Introduction (CPB) is discussed to promote a complicated and prolonged recovery after cardiac surgery Because failure of gastrointestinal function (3). Regional blood flow is regulated by many has been implicated in the development of factors influencing the circulation directly and systemic inflammatory response syndrome indirectly. However the renin-angiotensin sys- (SIRS), multiple organ dysfunction syndrome tem (RAS) appears to be an important factor (MODS), sepsis and multiple organ failure regulating intestinal blood flow during CPB (MOV) (1) (2), reduced gastrointestinal (4). It has been reported that activation of the blood flow during cardiopulmonary bypass renin-angiotensin system is associated with 44 M. Müller, M. Kwapisz, S. Klemm, H. Maxeiner, H. Akintürk, K. Valeske an increase in systemic vascular resistance nel blockers was continued until the day of during non-pulsatile CPB (5). Furthermore it surgery. Anesthesia was similar in all patients. has been shown that angiotensin-converting The morning of surgery the patients received enzyme (ACE) inhibitors can protect the in- flunitrazepam 2 mg and morphine sulfate 30 testine from ischemic injury after hemorrhage mg for oral premedication. Intravenous induc- and cardiogenic shock (6, 7). Quinaprilat is tion was performed using sufentanil (0.2 to the active metabolite of the non-sulphydryl 0.3 µg/kg), midazolam (0.05 to 0.1 mg/kg) ACE inhibitor quinapril. Its onset time after i.v. and pancuronium bromide (0.1 mg/kg). For application is within 15 min and its duration maintenance of anesthesia every 30 min of action is at least 12 h (8). Recent data sug- sufentanil 25 µg, and every 45 min midazo- gest that quinaprilat in contrast to enalaprilat lam 5 mg were given. Prior to cardiopul- improves endothelium-mediated vasodilation monary bypass (CPB) anesthesia was supple- (9). Therefore we used quinaprilat to evaluate mented with nitrous oxide. CPB was institut- the effects of intraoperative ACE inhibition on ed using a single two-stage venous and aortic gastric mucosal blood flow during moderate cannulation. CPB was performed in moderate hypothermic CPB in patients undergoing car- hypothermia (rectal temperature ≥ 33° C) us- diac surgery. Our hypothesis is that quinapri- ing non-pulsatile perfusion (2.4 l·min-1·m-2) lat will improve gastric mucosal blood flow with membrane oxygenators (Sorin 41; Sorin, during cardiac surgery with CPB. The primary Torino, Italy). Priming of the extracorporal cir- outcome variable to prove this is a change in cuit consisted of 2000 ml of Ringer´s solution LDF. and 250 ml of 5 % albumin solution and elec- trolytes. HTK (histidine tryptophane ketoglu- tarate) solution was used for cardioplegic ar- Methods rest. In all patients rewarming began using the integral heat exchanger of the oxygenator Patients, anesthesia and when the final distal anastomosis was started. cardiopulmonary bypass The acid-base management followed the al- pha-stat methodology. During CPB norepi- Thirty consecutive eligible patients undergo- nephrine was given to keep mean arterial ing elective CABG have been included in a pressure (MAP) above 50 mm Hg. When placebo controlled study. After approval by MAP was > 100 mm Hg during CPB sufen- the Local Ethics Committee, written informed tanil 0.2 µg/kg and midazolam 0.1 mg/kg consent was obtained from the patients. Pa- were given additionally followed by a va- tients with preexisting cardiac failure (ejec- sodilator when necessary. All patients receiv- tion fraction < 50 % as estimated by ventricu- ing vasodilators or vasoconstrictors at any lography), renal insufficiency (serum creati- time during the study period were removed nine > 2.0 mmol/l) or impaired liver function from the study. During CPB the hematocrit (GOT > 30 U/l, GPT > 30 U/l), and patients was held between 20 and 30 %. Arterial (Left who took ACE inhibitors in their history or mammarian artery) and autologous venous had previous unacceptable side effects from grafts were used in all patients. No calcium- ACE inhibitors were excluded from the study. blocking drugs were given to prevent arterial Three patients, refusing the informed con- spasm. The reperfusion period before wean- sent, were not enrolled in the study. Using a ing from CPB was one third of the aortic randomized sequence, the patients were cross-clamping time. Weaning from CPB was prospectively assigned to group A (quinapri- performed by optimizing preload and succes- lat 0.02 mg/kg, n = 10), group B (quinaprilat sively reducing pump flow without routine 0.04 mg/kg, n = 10), or group C (control, n = use of catecholamines or other inotropes. 10). Preoperative treatment such as nitrates, beta-adrenergic blockers and calcium chan- Effects of intraoperative angiotensin-converting enzyme inhibition ... 45 Measured parameters and data points averaged off-line by a blinded observator (M.M.). Steady state baseline measurements The following hemodynamic variables have after induction of anesthesia were recorded, been recorded: Heart rate (HR), mean arteri- and subsequent measurements were ex- al pressure (MAP), mean pulmonary artery pressed as a percentage of this value. A naso- pressure (MPAP), central venous pressure gastric tonometer catheter (TRIP NGS- (CVP), and pulmonary capillary wedge pres- Catheter, Tonometrics Division, Instrumentar- sure (PCWP). Cardiac output (CO) was meas- ium Corp.) in combination with an automat- ured by thermodilution (mean value of three ed tonometric measurement device (Tono- measurements; CO-Set, Baxter Healthcare cap TC 200, Tonometrics Division, Instrumen- Corp, Irvine, CA). Pressures were measured tarium Corp.) was used to assess the carbon with reference to the midaxillary line. Oxygen dioxide tension of the gastric mucosa delivery (DO2I) and Oxygen consumption (PmucCO2). The PCO2 gap was defined as the (VO2I) were calculated using the following difference between mucosal and arterial formula: DO2I = CI x CaO2 x 10; VO2I = CI x PCO2. (CaO2 - CvO2) x 10, where CI is the cardiac index, CaO2 is the arterial oxygen content and CvO2 is the mixed venous oxygen con- Experimental protocol tent. Microcirculatory blood flow was studied using laser Doppler flowmetry (MBF 3D, Baseline values for the variables were meas- Moor Instruments Ltd., Devon, UK). To meas- ured after induction of anesthesia (T0). The ure gastric mucosal blood flow a probe de- measurements were repeated during steady signed for endoscopic measurements (P6b, state of CPB (approximately 20 min. after Moor Instruments Ltd, Devon, UK) was used. start of CPB) (T1). Thereafter either quinapri- After calibration with a Moor instruments Ltd. lat in group A and B or saline solution (group motility standard kit the probe was inserted C) were given as an intravenous bolus. The through the lumen of a standard gastric tube. LDF measurements were performed after 5 After induction of general anesthesia and po- (T2), 10 (T3), 15 (T4) minutes during CPB as sitioning of the patient on the operating table well as 5 minutes after weaning off CPB (T5) the gastric tube was entered orally and sited and at the end of the operation (T6). The in the stomach. The correct placement of the tonometric measurements were repeated at gastric tube was confirmed by instilling air in- T4, T5 and T6. MAP was measured at all time to the gastric tube and auscultating over the points, whereas the other systemic variables epigastricum and by aspirating gastric con- were not assessed during CPB. tents. Thereafter the laser Doppler flow (LDF) probe was inserted through the gastric tube, and the mean red blood cell flux was dis- Statistical analysis played on the monitor. The correct position of the probe was verified by observing the For statistical analysis the SPSS 7.5 for Win- typical pulse-synchronous oscillations. When dows NT computer package was used. Data the laser Doppler signal was stable the probe are expressed as mean ± standard deviation was fixed by tape at the nasogastric tube.
Load more

Recommended publications
  • Accupril® (Quinapril Hydrochloride Tablets)
    Accupril® (Quinapril Hydrochloride Tablets) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ACCUPRIL as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION ACCUPRIL® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C25H30N2O5 •HCl and its structural formula is: Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. ACCUPRIL tablets contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. Each tablet also contains candelilla wax, crospovidone, gelatin, lactose, magnesium carbonate, magnesium stearate, synthetic red iron oxide, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure caused by intravenously administered angiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption.
    [Show full text]
  • Quinapril Tablets USP8289921/0720Frx Only
    QUINAPRIL- quinapril tablet American Health Packaging ---------- Quinapril Tablets USP 8289921/0720F Rx only WARNING: FETAL TOXICITY When pregnancy is detected, discontinue quinapril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity DESCRIPTION Quinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester of a non- sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C 25H 30N 2O 5•HCl and its structural formula is: Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. Quinapril tablets USP contain 5 mg (equivalent to 5.416 mg Quinapril Hydrochloride), 10 mg (equivalent to 10.832 mg Quinapril Hydrochloride), 20 mg (equivalent to 21.664 mg Quinapril Hydrochloride), or 40 mg (equivalent to 43.328 mg Quinapril Hydrochloride) of quinapril for oral administration. Each film-coated tablet also contains crospovidone, iron oxide yellow, lecithin, magnesium carbonate, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, povidone, talc, titanium dioxide and xanthan gum. CLINICAL PHARMACOLOGY Mechanism of Action Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation.
    [Show full text]
  • Interactions Between Antihypertensive Drugs and Food B
    11. INTERACTIONS:01. Interacción 29/11/12 14:38 Página 1866 Nutr Hosp. 2012;27(5):1866-1875 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Interactions between antihypertensive drugs and food B. Jáuregui-Garrido1 and I. Jáuregui-Lobera2 1Department of Cardiology. University Hospital Virgen del Rocío. Seville. Spain. 2Bromatology and Nutrition. Pablo de Olavide University. Seville. Spain. Abstract INTERACCIONES ENTRE FÁRMACOS ANTIHIPERTENSIVOS Y ALIMENTOS Objective: A drug interaction is defined as any alter- ation, pharmacokinetics and/or pharmacodynamics, Resumen produced by different substances, other drug treatments, dietary factors and habits such as drinking and smoking. Objetivo: la interacción de medicamentos se define como These interactions can affect the antihypertensive drugs, cualquier alteración, farmacocinética y/o farmacodiná- altering their therapeutic efficacy and causing toxic mica, producida por diferentes sustancias, otros tratamien- effects. The aim of this study was to conduct a review of tos, factores dietéticos y hábitos como beber y fumar. Estas available data about interactions between antihyperten- interacciones pueden afectar a los fármacos antihipertensi- sive agents and food. vos, alterando su eficacia terapéutica y causando efectos Methods: The purpose of this review was to report an tóxicos. El objetivo de este estudio fue realizar una revisión update of main findings with respect to the interactions de los datos disponibles acerca de las interacciones entre los between food and antihypertensive drugs
    [Show full text]
  • Preclinical Profile of Zofenopril: an Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties
    Cardiovascular Drug Reviews Vol. 17, No. 2, pp. 115–133 © 1999 Neva Press, Branford, Connecticut Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties A. Subissi, S. Evangelista and A. Giachetti Preclinical Development, Menarini Ricerche S.p.A., Firenze, Italy. Key Words: Angiotensin-converting enzyme inhibitor—Cardioprotection—Hypertension— Sulfhydryl—Zofenopril. INTRODUCTION The discovery of captopril, the prototype of orally active angiotensin-converting en- zyme inhibitors (ACEIs), represented a major breakthrough in the treatment of cardio- vascular diseases. Currently, captopril has four important indications: hypertension, con- gestive heart failure, acute myocardial infarction, and diabetic nephropathy. After the discovery of captopril, several new ACEIs were developed and introduced into medical practice. These new ACEIs are neither chemically nor pharmacologically identical; they differ in their chemical structure, functional groups (sulfhydryl in captopril, carboxyl in enalapril, or phosphinyl in fosinopril), active moiety (some are prodrugs), potency, an- cillary pharmacology, and pharmacokinetics. These and other important characteristics differentiate ACEIs and influence their ability to inhibit the enzyme in various organs. Since ACEIs appear to work by inhibiting angiotensin-converting enzyme (ACE) in critical tissues, tissue selectivity is one of the most important properties that varies with the individual ACEIs. An important question is whether different tissue-selectivity profiles of ACEIs in ani- mal experiments are clinically relevant. Although the clinical relevance is not yet firmly established, the emerging evidence indicates that some differences among ACEIs are clinically significant (4,6,28,43). The latest ACE inhibitor to reach the European market is zofenopril calcium. By February 1999, it was registered in all 15 European Community countries.
    [Show full text]
  • Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 10/09/2008
    Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 10/09/2008 Copyright © 2004 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected].
    [Show full text]
  • Angiotensin Modulators: ACE Inhibitors and Renin Inhibitors Therapeutic Class Review (TCR) August 28, 2013
    Angiotensin Modulators: ACE Inhibitors and Renin Inhibitors Therapeutic Class Review (TCR) August 28, 2013 Please Note: This clinical document has been retired. It can be used as a historical reference. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
    [Show full text]
  • Transport of Angiotensin-Converting Enzyme Inhibitors by H /Peptide
    JPET Fast Forward. Published on August 19, 2008 as DOI: 10.1124/jpet.108.143339 JPET FastThis articleForward. has not Publishedbeen copyedited on and August formatted. 19, The 2008final version as DOI:10.1124/jpet.108.143339 may differ from this version. JPET/2008/143339 Title Page Transport of Angiotensin-converting Enzyme Inhibitors by H+/Peptide Transporters Revisited Ilka Knütter, Claudia Wollesky, Gabor Kottra, Martin G. Hahn, Wiebke Downloaded from Fischer, Katja Zebisch, Reinhard H. H. Neubert, Hannelore Daniel, and Matthias Brandsch jpet.aspetjournals.org Membrane Transport Group, Biozentrum, Martin-Luther-University Halle-Wittenberg, Germany (I.K., C.W., M.G.H., W.F., K.Z., M.B.); Molecular Nutrition Unit, Center of at ASPET Journals on October 2, 2021 Life and Food Science, Technical University of Munich, Germany (G.K., H.D.); and Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Germany (R.H.H.N.) 1 Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on August 19, 2008 as DOI: 10.1124/jpet.108.143339 This article has not been copyedited and formatted. The final version may differ from this version. JPET/2008/143339 Running Title: Transport of ACE Inhibitors by Peptide Transporters Correspondence: Matthias Brandsch Biozentrum of the Martin-Luther-University Halle-Wittenberg Membrane Transport Group Weinbergweg 22 D-06120 Halle, Germany Downloaded from Tel.: 49-345-552-1630 Fax: 49-345-552-7258 jpet.aspetjournals.org E-mail: [email protected] Text pages: 16 at ASPET Journals on October 2, 2021 Tables: 2 Figures: 4 References: 40 Words in the Abstract: 243 Words in the Introduction: 678 Words in the Discussion: 1386 Suggested Section Assignment: Metabolism, Transport, and Pharmacogenomics ABBREVIATIONS: ACE, Angiotensin-converting enzyme; PEPT1, H+/peptide transporter 1; PEPT2, H+/peptide transporter 2; HRPE, human retinal pigment epithelium; rMVA, recombinant modified vaccinia virus Ankara 2 JPET Fast Forward.
    [Show full text]
  • Arrow – Quinapril 10, Film-Coated Tablets, 10 Mg Arrow – Quinapril 20, Film-Coated Tablets, 20 Mg
    NEW ZEALAND DATA SHEET 1. NAME OF THE MEDICINE Arrow – Quinapril 5, film-coated tablets, 5 mg Arrow – Quinapril 10, film-coated tablets, 10 mg Arrow – Quinapril 20, film-coated tablets, 20 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg, 10 mg or 20 mg of quinapril as quinapril hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets 5 mg: Yellow, oval, biconvex film coated tablets, one side scored and embossed ‘5’ on the other side. Tablets 10 mg: White to almost white, round, biconvex film coated tablets, one side scored and embossed ‘10’ on the other side. Tablets 20 mg: Yellow, round, biconvex film coated tablets, one side scored and embossed ‘20’ on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Hypertension Quinapril is indicated for the treatment of essential hypertension. Quinapril is effective as monotherapy or concomitantly with diuretics and beta-blockers in patients with hypertension. Congestive Heart Failure Quinapril is effective in the treatment of congestive heart failure when given concomitantly with a diuretic and/or digoxin. 4.2 Dose and method of administration Hypertension in Adults Monotherapy The recommended initial dosage of quinapril in patients not on diuretics is 10 mg once daily. Depending upon clinical response, the patient's dosage may be titrated (by doubling the dose) to a maintenance dosage of 20 mg to 40 mg/day given as a single dose or divided into two doses. Generally dosage adjustments should be made at intervals of four weeks. Long-term control is maintained in most patients with a single daily dosage regimen.
    [Show full text]
  • Fixed Combination of Atorvastatin/Perindopril — Modern Prevention of Cardiovascular Events
    REVIEW ARTICLE Folia Cardiologica 2019 vol. 14, no. 4, pages 376–383 Copyright © 2019 Via Medica ISSN 2353–7752 Fixed combination of atorvastatin/perindopril — modern prevention of cardiovascular events Preparat złożony atorwastatyna/perindopril — nowoczesna prewencja zdarzeń sercowo-naczyniowych Iwona Gorczyca●iD, Beata Wożakowska-Kapłon●iD 1st Department of Cardiology and Electrotherapy, Świętokrzyskie Centre of Cardiology, Kielce, Poland Faculty of Medicine and Health Sciences, Jan Kochanowski University in Kielce, Poland Artykuł jest tłumaczeniem pracy: Gorczyca I, Wożakowska-Kapłon B. Preparat złożony atorwastatyna/perindopril — nowoczesna prewencja zdarzeń sercowo-naczyniowych. Folia Cardiol. 2019; 14 (4): 368–375. DOI: 10.5603/FC.2019.0095. Należy cytować wersję pierwotną Abstract Cardiovascular diseases are the leading cause of death in Poland. The most common cardiovascular risk factors are dyslipidemia and hypertension. Unfortunately, the percentage of patients with well-controlled dyslipidemia and hyper- tension remains very low. This is mainly due to insufficient statin therapy. Perindopril and atorvastatin are substances with a documented efficacy in reducing the incidence of cardiovascular events. The use of these drugs in one capsule can cause a significant increase in the percentage of patients properly treated and reaching the target values of blood pressure and LDL-cholesterol. Key words: hypertension, hypercholesterolemia, perindopril, atorvastatin, combined therapy Folia Cardiologica 2019; 14, 4: 376–383 Introduction Cardiovascular diseases remain the leading cause of death in Europe [1, 2]. In the Polish population, according to the results of the NATPOL study [3], dyslipidemia and hypertension are the two most common cardiovascular risk factors. Dyslipidemia occurs in 18 million Poles, and 10.5 million adult Poles suffer from hypertension.
    [Show full text]
  • Cardiovascular: Direct Renin Inhibitors and Combinations
    Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 01/03/2011 Copyright © 2004 - 2011 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd. Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected].
    [Show full text]
  • (Pty) Ltd Page 1 of 15 ACCUPRIL Approved Package Insert
    Pfizer Laboratories (Pty) Ltd Page 1 of 15 ACCUPRIL Proposed Package Insert – 09 September 2021 PROPOSED PACKAGE INSERT SCHEDULING STATUS: S3 PROPRIETARY NAMES (AND DOSAGE FORMS): ACCUPRIL® 5 mg (tablet) ACCUPRIL® 10 mg (tablet) ACCUPRIL® 20 mg (tablet) ACCUPRIL® 40 mg (tablet) COMPOSITION: ACCUPRIL 5 mg: Each tablet contains quinapril hydrochloride equivalent to 5 mg quinapril. ACCUPRIL 10 mg: Each tablet contains quinapril hydrochloride equivalent to 10 mg quinapril. ACCUPRIL 20 mg: Each tablet contains quinapril hydrochloride equivalent to 20 mg quinapril. ACCUPRIL 40 mg: Each tablet contains quinapril hydrochloride equivalent to 40 mg quinapril. PHARMACOLOGICAL CLASSIFICATION: A 7.1.3 Vascular medicines - other hypotensives PHARMACOLOGICAL ACTION: Quinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester of a long-acting nonsulfhydryl, specific angiotensin-converting enzyme (ACE) inhibitor. Quinapril is rapidly deesterified to quinaprilat (quinapril diacid, the principal metabolite) which, in human and animal studies, is an angiotensin-converting enzyme inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor angiotensin II which is involved in This submission: Removal of export market registration details Pfizer Laboratories (Pty) Ltd Page 2 of 15 ACCUPRIL Proposed Package Insert – 09 September 2021 vascular control and function through many different mechanisms, including stimulation of aldosterone secretion by the adrenal cortex. The primary mode of action of quinapril in humans and animals is to inhibit ACE, thereby decreasing vasopressor activity and aldosterone secretion. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. Quinapril has antihypertensive activity in the presence of low to normal plasma renin concentrations.
    [Show full text]
  • Telmisartan Versus Angiotension-Converting
    Journal of Human Hypertension (2009) 23, 339–349 & 2009 Macmillan Publishers Limited All rights reserved 0950-9240/09 $32.00 www.nature.com/jhh ORIGINAL ARTICLE Telmisartan versus angiotension- converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials Z Zou1,3, G-L Xi2,3, H-B Yuan1, Q-F Zhu1 and X-Y Shi1 1Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China and 2Center for New Drug Evaluation, Institute of Basic Medical Science, Second Military Medical University, Shanghai, People’s Republic of China Telmisartan and angiotensin-converting enzyme inhibi- 0.33–2.62). Telmisartan also showed a greater DBP tors (ACEIs) are both effective and widely used response rate than enalapril (relative risk (RR) 1.15, antihypertensive drugs targeting renin–angiotensin– 95% CI 1.05–1.26), ramipril (RR 1.34, 95% CI 1.11–1.61) aldosterone system. The study aimed to estimate the and perindopril (RR 1.22, 95% CI 1.05–1.41). There was efficacy and tolerability of telmisartan in comparison no statistical difference in DBP reduction or therapeutic with different ACEIs as monotherapy in the treatment of response rate between telmisartan and lisinopril (WMD hypertension. Cochrane Central Register of Controlled À0.30, 95% CI À0.65 to 0.05; RR 0.99, 95% CI 0.80–1.23, Trials, PubMed and Embase were searched for relevant respectively). Telmisartan had fewer drug-related studies. A meta-analysis of all randomized controlled adverse events than enalapril (RR 0.57, 95% CI 0.44–0.74), trials fulfilling the predefined criteria was performed.
    [Show full text]